S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
NASDAQ:SAVA

Cassava Sciences (SAVA) Stock Forecast, Price & News

$20.82
+1.58 (+8.21%)
(As of 05/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$18.81
$22.47
50-Day Range
$17.22
$40.83
52-Week Range
$15.72
$146.16
Volume
1.63 million shs
Average Volume
1.80 million shs
Market Capitalization
$834.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.93
30 days | 90 days | 365 days | Advanced Chart
Receive SAVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Cassava Sciences logo

About Cassava Sciences

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Headlines

How Is The Market Feeling About Cassava Sciences?
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAVA
Employees
24
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$5.92 per share

Profitability

Net Income
$-32.38 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
36,033,000
Market Cap
$834.49 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/17/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.84 out of 5 stars

Medical Sector

755th out of 1,423 stocks

Pharmaceutical Preparations Industry

361st out of 678 stocks

Analyst Opinion: 3.2Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













Cassava Sciences (NASDAQ:SAVA) Frequently Asked Questions

Is Cassava Sciences a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Cassava Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares.
View analyst ratings for Cassava Sciences
or view top-rated stocks.

When is Cassava Sciences' next earnings date?

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Cassava Sciences
.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) released its quarterly earnings data on Thursday, May, 5th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.02.
View Cassava Sciences' earnings history
.

When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work?

Cassava Sciences shares reverse split on the morning of Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SAVA?

5 equities research analysts have issued twelve-month price targets for Cassava Sciences' shares. Their forecasts range from $58.00 to $215.00. On average, they expect Cassava Sciences' share price to reach $124.25 in the next twelve months. This suggests a possible upside of 496.8% from the stock's current price.
View analysts' price targets for Cassava Sciences
or view top-rated stocks among Wall Street analysts.

Who are Cassava Sciences' key executives?
Cassava Sciences' management team includes the following people:
  • Mr. Remi Barbier, Founder, Chairman, Pres & CEO (Age 62, Pay $1.74M)
  • Mr. Eric J. Schoen, Chief Financial Officer (Age 54, Pay $776.93k)
  • Dr. Nadav Friedmann M.D., Ph.D., Chief Medical Officer & Director (Age 79, Pay $765k)
  • Dr. James W. Kupiec M.D., Chief Clinical Devel. Officer
  • Dr. George Thornton, Sr. VP of Technology
  • Mr. Michael Zamloot, Sr. VP of Technical Operations
  • Dr. Lindsay H. Burns Ph.D., Sr. VP of Neuroscience
What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.75%), Vanguard Group Inc. (4.93%), State Street Corp (2.63%), Northern Trust Corp (0.91%), Group One Trading L.P. (0.00%) and Charles Schwab Investment Management Inc. (0.68%). Company insiders that own Cassava Sciences stock include Eric Schoen, Remi Barbier and Sanford Robertson.
View institutional ownership trends for Cassava Sciences
.

Which institutional investors are selling Cassava Sciences stock?

SAVA stock was sold by a variety of institutional investors in the last quarter, including Affinity Asset Advisors LLC, IMC Chicago LLC, Sculptor Capital LP, Vanguard Group Inc., BlackRock Inc., Principal Financial Group Inc., Baird Financial Group Inc., and Group One Trading L.P..
View insider buying and selling activity for Cassava Sciences
or view top insider-selling stocks.

Which institutional investors are buying Cassava Sciences stock?

SAVA stock was purchased by a variety of institutional investors in the last quarter, including Simplex Trading LLC, State Street Corp, Advisor Group Holdings Inc., Raymond James & Associates, MetLife Investment Management LLC, Charles Schwab Investment Management Inc., Darwin Advisors LLC, and Swiss National Bank. Company insiders that have bought Cassava Sciences stock in the last two years include Eric Schoen, Remi Barbier, and Sanford Robertson.
View insider buying and selling activity for Cassava Sciences
or or view top insider-buying stocks.

How do I buy shares of Cassava Sciences?

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $20.82.

How much money does Cassava Sciences make?

Cassava Sciences has a market capitalization of $834.49 million. The company earns $-32.38 million in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does Cassava Sciences have?

Cassava Sciences employs 24 workers across the globe.

What is Cassava Sciences' official website?

The official website for Cassava Sciences is www.cassavasciences.com.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at (512) 501-2444, via email at [email protected], or via fax at 512-501-0414.

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.